Evidence map›Paper›PMID 38316745›Full record

ArticleThe AAPS journal2024

Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development.

Amanda Hays, Mark Wissel, Kelly Colletti, Russell Soon, Mitra Azadeh, Justin Smith, Rajitha Doddareddy, Melanie Chalfant, Wendy Adamowicz, Swarna Suba Ramaswamy and 27 more

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Analysis of qPCR Data: From PCR Efficiency to Absolute Target Quantity.International journal of molecular sciences · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Amanda HaysBioAgilytix Laboratories, Durham, North Carolina, USA. amanda.hays@bioagilytix.com.
Mark WisselEurofins Viracor BioPharma Services, Inc., Lenexa, Kansas, USA.
Kelly CollettiBeam Therapeutics, Cambridge, Massachusetts, USA.
Russell SoonBioMarin Pharmaceutical Inc., Novato, California, USA.
Mitra AzadehUltragenyx Pharmaceutical Inc., Novato, Calfornia, USA.
Justin SmithPfizer Inc, Groton, Connecticut, USA.
Rajitha DoddareddyMerck & Co., Inc., Rahway, New Jersey, USA.
Melanie ChalfantGSK, Collegeville, Pennsylvania, USA.
Wendy AdamowiczPPD Clinical Research, Thermo Fisher Scientific, Richmond, Virginia, USA.
Swarna Suba RamaswamyEli Lilly and Company, Indianapolis, Indiana, USA.
Sanjay L DholakiyaBristol Myers Squibb, Princeton, New Jersey, USA.
Sebastian GuelmanGenentech, Inc., South San Francisco, California, USA.
Bryan GullickBioAgilytix Laboratories, Durham, North Carolina, USA.
Jennifer DurhamBioAgilytix Laboratories, Boston, Massachusetts, USA.
Keith RennierLabcorp Drug Development, Greenfield, Indiana, USA.
Pruthvi NagillaAsher Biotherapeutics, Inc., South San Francisco, California, USA.
Anamica MuruganandhamBioAgilytix Laboratories, Durham, North Carolina, USA.
Manisha DiazEurofins Viracor BioPharma Services, Inc., Lenexa, Kansas, USA.
Cassandra TierneyPfizer Inc, Groton, Connecticut, USA.
Kaarthik JohnREGENXBIO Inc., Rockville, Maryland, USA.
Jenny ValentineRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Timothy LockmanPPD Clinical Research, Thermo Fisher Scientific, Richmond, Virginia, USA.
Hsing-Yin LiuJanssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Benjamin MoritzCharles River Labs, Reno, Nevada, USA.
Jean Paul OuedraogoCharles River Labs, Senneville, Québec, Canada.
Marie-Soleil PicheCharles River Labs, Senneville, Québec, Canada.
Muriel SmetSanofi, Ghent, Belgium.
Jacqueline MurphyJanssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Kaylyn KoenigAltasciences Preclinical Seattle LLC, Everett, Washington, USA.
Agnes ZyburaLabcorp Drug Development, Greenfield, Indiana, USA.
Carrie VyhlidalKCAS Bioanalytical and Biomarker Services, Shawnee, Kansas, USA.
Jonathan MercierFlowmetric Life Sciences, Inc., Spring House, Pennsylvania, USA.
Niketa JaniBioAgilytix Laboratories, Boston, Massachusetts, USA.
Mikael KubistaInstitute of Biotechnology Czech Academy of Sciences, Prague, Czech Republic.
Donald BirchAltasciences Preclinical Seattle LLC, Everett, Washington, USA.
Karlin MorseAltasciences Preclinical Seattle LLC, Everett, Washington, USA.
Oskar JohanssonTATAA Biocenter, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emerging use of qPCR and dPCR in regulated bioanalysis and absence of regulatory guidance on assay validations for these platforms has resulted in discussions on lack of harmonization on assay design and appropriate acceptance criteria for these assays. Both qPCR and dPCR are extensively used to answer bioanalytical questions for novel modalities such as cell and gene therapies. Following cross-industry conversations on the lack of information and guidelines for these assays, an American Association of Pharmaceutical Scientists working group was formed to address these gaps by bringing together 37 industry experts from 24 organizations to discuss best practices to gain a better understanding in the industry and facilitate filings to health authorities. Herein, this team provides considerations on assay design, development, and validation testing for PCR assays that are used in cell and gene therapies including (1) biodistribution; (2) transgene expression; (3) viral shedding; (4) and persistence or cellular kinetics of cell therapies.

Indexed as

Drug DevelopmentGenetic TherapyPolymerase Chain ReactionTissue DistributionAAVbiodistributioncell therapycellular kineticsdPCRgene therapyqPCRRT-qPCRsheddingtransgene expression

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.